HPV16-E6-29_38
Human papillomavirus 16 E6 peptide epitope TIHDIILECV (aa 29-38)
TIHDIILECV Amino Acids · MW: 1218.4
Amino Acids
TIHDIILECV
Molecular Weight
1218.4
Half-life
minutes-hours
Research Score
4.1
Studies
88
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is HPV16-E6-29_38?
A documented HPV16-derived epitope used in therapeutic vaccine research against HPV-associated cancers. It provides a defined viral target for inducing cytotoxic T-cell responses in infected or transformed cells.
Key Benefits & Mechanisms
viral tumor antigen targeting
CD8+ T-cell priming
supports HPV-specific immune readouts
Research Summary
HPV16 E6 epitopes have been incorporated into peptide vaccine formats and dendritic-cell strategies in clinical research. The 29-38 region is a bona fide T-cell target and is distinct from the excluded E7 11-20 epitope.
Related Peptides
PADRE
Pan HLA-DR-binding helper T-cell epitope
PADRE is a synthetic promiscuous CD4+ helper T-cell epitope designed to bind many HLA-DR alleles. It is widely used in peptide vaccine research to improve helper T-cell priming and strengthen responses to linked antigens.
Vaccine PeptidesSIINFEKL
Ovalbumin 257-264 epitope (SIINFEKL)
SIINFEKL is a classic MHC class I epitope derived from chicken ovalbumin. It is one of the most widely used model peptides for studying antigen presentation, cytotoxic T-cell priming, and peptide vaccine platforms.
Vaccine PeptidesAAGIGILTV
MART-1/Melan-A 26-35 epitope
AAGIGILTV is a well-known HLA-A2-restricted epitope from the melanocyte differentiation antigen MART-1/Melan-A. It has been studied in melanoma vaccine research to generate antigen-specific T-cell responses against tumor cells.
Vaccine PeptidesHPV16 E7(11-20)
Human papillomavirus type 16 E7 11-20 epitope
HPV16 E7(11-20) is a documented cytotoxic T-cell epitope derived from the HPV16 E7 oncoprotein. It has been used in therapeutic HPV vaccine research to stimulate epitope-specific cellular immunity.
Vaccine Peptides